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Mitogen-activated protein (MAP) kinases have a central role in
several biological functions, including cell adhesion and spreading,
chemotaxis, cell cycle progression, differentiation, and apoptosis.
Extracellular signal-regulated kinase 8 (Erk8) is a largeMAP kinase
whose activity is controlled by serum and the c-Src non-receptor
tyrosine kinase.Here, we show thatRET/PTC3, an activated formof
the RET proto-oncogene, was able to activate Erk8, and we demon-
strate that such MAP kinase participated in RET/PTC3-dependent
stimulation of the c-jun promoter. By using RET/PTC3 molecules
mutated in specific tyrosine autophosphorylation sites, we charac-
terized Tyr981, a known binding site for c-Src, as a major determi-
nant of RET/PTC3-induced Erk8 activation, although, surprisingly,
the underlyingmechanism did not strictly depend on the activity of
Src. In contrast, we present evidence that RET/PTC3 acts on Erk8
through Tyr981-mediated activation of c-Abl. Furthermore, we
localized the region responsible for the modulation of Erk8 activity
by the RET/PTC3 and Abl oncogenes in the Erk8 C-terminal
domain. Altogether, these results support a role for Erk8 as a novel
effector of RET/PTC3 and, therefore, RET biological functions.
MAP3 kinases are a family of proline-directed serine/threonine
kinases that play a central role in signal transduction in all eukaryotic
cells, from yeast to humans (1). They coordinate signaling from a variety
of extracellular and intracellular stimuli by acting as components of
modular systems that involve other kinases and regulatory proteins.
These stimuli induce specific phosphorylation on a conservedThr-Xaa-
Tyr motif present in all MAP kinases, thereby inducing their activation.
Consequently, these proteins transmit the signals to a vast array of cel-
lular regulatory proteins including protein kinases, transcription fac-
tors, cytoskeletal proteins, and other enzymes (1).
Erk8 is the last identified member of the MAP kinase family of pro-
teins (2). Expressed in humans at high levels in the brain, kidney, and
lung, its activity can be modulated by serum and c-Src (2). Although
possessing a very typicalMAPkinase domain, Erk8 also presents a pecu-
liarly long C-terminal domain containing two putative SH3-binding
sites (2). Information concerning its upstream activators, downstream
effectors, and cellular functions is still extremely limited.
RET is a typical trans-membrane receptor tyrosine-kinase, essential
for the development of the sympathetic, parasympathetic, and enteric
nervous system and of the kidney (3). In complex with four glyco-
sylphosphatidylinositol-anchored coreceptors, GFR- 1–4, the RET
protein binds growth factors of the glial-derived neurotrophic factor
family, mediating their intracellular signaling (4). As for other receptor
tyrosine-kinases, ligand interaction triggers autophosphorylation of dif-
ferent RET intracellular tyrosine residues that work as docking sites for
several adaptor and effector signaling molecules (5). Among such
tyrosines, although Tyr981 is a binding site for c-Src, Tyr1062 has been
shown to mediate the interactions with most of RET effectors and to be
responsible for activation of the Ras/Erk, phosphatidylinositol 3-kinase/
Akt, Jnk, p38, and Erk5 signaling pathways (6). Finally, Tyr1015 is a rec-
ognized docking site for phospholipase C  (7).
Gain-of-function mutations of RET have been repeatedly described
in several human tumors (8). RET germline point mutations are in fact
responsible for the three clinical subtypes of the multiple endocrine
neoplasias type 2 (MEN2) syndrome, MEN2A, MEN2B, and familial
medullary thyroid carcinoma (5). In addition, fusion of the intracellular
kinase domain ofRETwith heterologous genes, caused by chromosomal
inversions or translocations, generates the RET/PTC oncogenes, which
represent the genetic hallmark of papillary thyroid carcinomas (PTC),
accounting formore than 80–90% of all thyroid carcinomas (9). Among
the at least 10 different RET/PTC rearrangements, RET/PTC1 and
RET/PTC3, generated by the fusion with theH4 and RFG genes, respec-
tively, are the most common types, accounting for more than 90% of all
rearrangements (10).
MATERIALS ANDMETHODS
Antibodies—As primary antibodies, we used rabbit polyclonal anti-
sera to Erk2 (C-14) (Santa Cruz Biotechnology), phospho-MAPK (p42/
p44) (Cell Signaling), RET and phospho-RET (phospho-Tyr905) (11),
and mouse monoclonal antibodies to enhanced green fluorescent pro-
tein, AU5, and HA epitopes (Berkeley Antibody Company), Src (Ab-1;
Oncogene Science), c-Abl (Pharmingen), and phospho-tyrosine, PY
(Santa Cruz Biotechnology and Upstate Biotechnology).
Expression Vectors—The expression vectors pCEFLP-SrcYF (consti-
tutively active) and pCEFLP-SrcYF KM (dominant negative) were
obtained by subcloning the corresponding cDNA obtained from pSM-
SrcYF and pSM-SrcYF KM, kindly provided by H. Varmus (12). The
HA-tagged form of Erk8 was generated by cloning the corresponding
cDNA, kindly provided by M. Abe (2), in the pCEFL-HA vector. The
HA-tagged forms of Erk8 deletion mutants (1–504; 1–486; 1–386;
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1–373) were generated by cloning the corresponding cDNAs, obtained
by PCR amplification, in the pCEFL-HA vector. The expression vector
for the dominant negative Erk8 KR molecule was also provided by M.
Abe (2). To generate the pCEFL-HA-Erk8 expression vector, we
amplified by PCR the corresponding cDNA using an “expressed
sequence tag” obtained from ResGen (Clone ID 5742965). These
sequence data have been submitted to the GenBankTM data base under
accession number AY994058. pCDNA3-RET/PTC3 and pBABE-RET/
MEN2B expression plasmid have been described previously (13, 14).
The RET/PTC3Y981, RET/PTC3Y1015, RET/PTC3Y1062, RET/PTC3
Kindead, and RET/PTC3V804 expression plasmid were generated by the
QuikChangeTM site-directed mutagenesis kit (Stratagene), using
pCDNA3-PTC3 as a template. Expression vectors for the activated form
of c-Abl (Abl Act) and Bcr/Abl p210 (Bcr/Abl) have been described
previously (15, 16). The dominant negative c-Abl (Abl-KD) expression
vector was obtained bymutating a critical lysine in the kinase domain of
c-Abl, contained in the pCEFL-AU5 vector. The c-myc and c-jun pro-
moter reporter plasmids, pMyc-Luc and pJLuc, respectively, and the
pCDNAIII--galactosidase expression vector have been described pre-
viously (12, 17). The identity and integrity of the different clones were
confirmed by dideoxy DNA sequencing. For each plasmid, additional
information will be provided upon request.
Western Blot Analysis—Lysates of total cellular proteins or immuno-
precipitates were analyzed by protein immunoblotting after SDS-PAGE
with specific rabbit antisera or mouse monoclonal antibodies. Immu-
nocomplexes were visualized by enhanced chemiluminescence detec-
tion (ECL or ECL Plus, Amersham Biosciences) with the use of goat
antiserum to rabbit or mouse immunoglobulin G, coupled to horserad-
ish peroxidase (Amersham Biosciences).
Reagents—The PP1 inhibitor was purchased from BIOMOL. PDGF
was purchased from Serologicals Corp.
Cell Culture and Transfections—293T, Cal62, Kat4, and ARO cells
weremaintained in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum, 2 mM L-glutamine, and 100 units/ml pen-
icillin-streptomycin (Invitrogen). NIH 3T3 fibroblasts were maintained
in Dulbecco’s modified Eagle’s medium supplemented with 10% calf
bovine serum (BioWhittaker), 2mM L-glutamine, and 100 units/ml pen-
icillin-streptomycin (Invitrogen). Rat Pc cells were maintained in
Coon’s modified Ham’s F12 medium supplemented with 5% calf serum
and a mixture of six hormones, including 10 milliunits/ml thyrotropin,
10 nM hydrocortisone, 10 g/ml insulin, 5 g/ml apo-transferrin, 10
ng/ml somatostatin, and 10 ng/ml glycyl-histidyl-lysin (Sigma). 293T
and NIH 3T3 cells were transfected by the Lipofectamine reagent
(Invitrogen), whereas ARO cells were transfected by the Lipofectamine
2000 reagent (Invitrogen), respectively, in accordance with the manu-
facturer’s instructions. For transfections, 200 ng of HA-Erk8 and HA-
Erk8 and 100 ng of SrcYF, Abl Act, Bcr/Abl, and of the different Ptc3
expression vectors were always used.
Reporter Gene Assays—NIH 3T3 cells were transfected with different
expression plasmids together with 100 ng of the pMyc Luc reporter
plasmid. ARO cells were transfected with different expression plasmids
together with 20 ng of the pJLuc reporter plasmid. After a 24-h incuba-
tion in serum-free medium, the cells were lysed using reporter lysis
buffer (Promega). Luciferase activity present in cellular lysates was
assayed using D-luciferin and ATP as substrates, and light emission was
quantitated using the 20n/20n luminometer as specified by the manu-
facturer (Turner BioSystems).
RNA Extraction, RT-PCR, and Quantitative Real-time PCR—Total
RNA was isolated using the RNeasy kit (Qiagen) and subjected to on-
column DNase digestion with the RNase-free DNase set (Qiagen)
according to the manufacturer’s instructions. The quality of RNA was
verified by electrophoresis through 1% agarose gel and visualized with
ethidium bromide. We synthesized random-primed first-strand cDNA
in a 50-l reaction volume starting from 2 g of RNA using the Gene-
Amp RNA PCR core kit (Applied Biosystems). Quantitative (real-time)
reverse transcription-polymerase chain reactions (qRT-PCRs) were
performed by using the SYBR Green PCR master mix (Applied Biosys-
tems) in the iCycler apparatus (Bio-Rad). Amplification reactions (25-l
final reaction volume) contained 200 nM of each primer, 3 mM MgCl2,
300 M deoxyribonucleoside triphosphates (dNTPs), 1 SYBR Green
PCR buffer (Applied Biosystems), 0.1 units/l AmpliTaq Gold DNA
Polymerase (Applied Biosystems), 0.01 units/l Amp Erase (Applied
Biosystems), RNase-free water, and 2 l of cDNA samples. Thermal
cycling conditionswere optimized standard conditions and are available
upon request. To verify the absence of nonspecific products, we per-
formed 80 cycles of melting (55 °C for 10 s). The melting curve con-
firmed that a single product was generated. Amplification was moni-
tored bymeasuring the increase in fluorescence caused by the binding of
SYBR Green to double-stranded DNA. Primers were synthesized by
MWG Biotech. Nucleotide sequences of the primers used in this study
were as follows: qErk8Forw, 5-GGAGTTTGGGGACCATCC-3, and
qErk8Rev, 5-GCGTTCAGGTCAGTGTCC-3.
Src in Vitro Kinase Assay—Cells were lysed in a buffer containing 50
mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% (v/v) Nonidet P-40, 1 mM
EDTA, 50 mM NaF, 20 mM sodium pyrophosphate, 1 mM sodium van-
adate, 2 mM phenylmethylsulfonyl fluoride, and 0.2 mg/ml each aproti-
nin and leupeptin. Lysates were centrifuged at 10,000 g for 30min and
immunoprecipitated by incubating 1 mg of total proteins with anti-Src
antibodies for 60 min at 4 °C. Immunocomplexes were recovered by
incubation with protein G-Sepharose beads (Amersham Biosciences)
on a rotating platform at 4 °C for 60 min. After three washes with lysis
buffer, the immunoprecipitates were washed with kinase buffer (20 mM
Tris-HCl (pH 7.0), 5 mM MgCl2) and resuspended in 30 l of kinase
buffer, 10 mCi of [-32P]ATP (10,000 Ci/mmol, Amersham Bio-
sciences), and 10 mM cold ATP. After 30 min of incubation at room
temperature, the beads were washed twice with lysis buffer, and the
reaction was terminated by adding an equal volume of SDS-gel loading
buffer (62.5mMTris-HCl (pH 6.8), 2% SDS, 5% glycerol, 0.7 M 2-mer-
captoethanol, and 0.25% bromphenol blue). When indicated, 5 mg of
acid-denatured enolase were added to the reaction (Roche Applied Sci-
ence). The samples were electrophoresed on SDS-10% polyacrylamide
gel. After the run, gels were incubated three times for 30 min in a fixing
solution (20%methanol, 10% acetic acid), dried, and processed for auto-
radiography with phosphor screens. Laser densitometry was used to
quantitate Src kinase activity.
RESULTS
Erk8 Is Activated by a RET-dependent Signaling Pathway—We per-
formed an in silico analysis of Erk8 gene expression in mouse tissues
through the public Mouse Gene Prediction Database resource (18).
Among other tissues, the mouse orthologue Erk8 gene was expressed at
very high levels in the thyroid. To verify Erk8 expression also in human
thyroid-derived cell lines, we next performed qRT-PCR in three human
anaplastic thyroid carcinoma cell lines, ARO, Cal62, and Kat4. qRT-
PCR evidenced high expression of Erk8 in the three human cell lines
tested, whereas as a control, the human-specific primers did not detect
any signal in a rat papillary thyroid carcinoma cell line, Pc (Fig. 1A).
These data therefore suggest a role for Erk8 in signaling pathways
involved in the homeostasis and/or pathology of the thyroid. As RET/
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FIGURE 1. A, Erk8 expression in human thyroid cancer cell lines. After RNA extraction, quantitative RT-PCRwas performed to evaluate Erk8 expression in human ARO, Kat4, and Cal62
cell lines. As a control (contr) for the specificity of the primers, rat Pc cells were also analyzed. B, schematic representation of the wild-type RET protein and of its activated form, the
RET/PTC3 oncogene. The position of three tyrosine autophosphorylation sites and of important protein domains are also shown. Numbers indicating RET/PTC3 tyrosine residues
correspond to their position in thewild-typeRET receptor. SP, signal peptide;TMD, trans-membranedomain;TK, tyrosine kinase;Y, tyrosine;RFG, RET fusedgene.C, analysis ofHA-Erk8
activation in 293T cells cotransfectedwith the RET/PTC3 (PTC3) and Src YF expression vectors and analyzed byWestern blot with anti-phosphoMAPK (-P-MAPK) antisera. Activation
of endogenous Erk2 by RET/PTC3 and Src YF was used as an additional control for the activity of the two oncogenes. The expression of HA-Erk8 (-HA panel), Erk2 (-Erk2 panel),
RET/PTC3 (-RET panel), and Src YF (-Src panel) was also confirmed. P, phospho. D, analysis of HA-Erk8 activation in 293T cells cotransfected with the increasing amounts of
RET/MEN2B (MEN2B) andRET/PTC3 (PTC3) expression vectors andanalyzedbyWesternblotwith anti-phosphoMAPKantisera. TheexpressionofHA-Erk8 (-HApanel)was confirmed.
Control, cells transfected with -galactosidase; , anti.
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PTC oncogenes are frequently involved in human papillary thyroid car-
cinomas (5), we decided to investigate their ability to modulate Erk8
activation. In particular, we investigated the role of RET/PTC3, a chi-
meric oncogene generated by the fusion of RET with the RFG gene
(Fig. 1B) (19).
As an approach to score Erk8 activation, we used an anti-phospho-
MAPK (Erk2) antibody that recognizes phosphorylation in the con-
served MAP kinase TEY motif. We performedWestern blot analysis of
293T cells transfected with an HA epitope-tagged form of the Erk8
kinase, as described previously by Abe et al. (2), and then distinguished
the transfected HA-Erk8 and the endogenous Erk2 by their different
molecular masses,60 and45 kDa, respectively. As shown in Fig. 1C,
RET/PTC3 overexpression readily induced Erk8 activation at a level
comparable with an activated form of c-Src (Src YF), used as a positive
control (2). Of note, no signal in the60-kDa range was detected in the
absence of HA-Erk8 transfection (Fig. 1C), indicating that the anti-
phospho-MAPK antisera specifically recognized the Erk8 protein. As an
additional control for the activity of RET/PTC3 and Src YF, both pro-
teins activated the Erk2MAP kinase (Fig. 1C), also scored by anti-phos-
pho-MAPKWestern blot.
As the RET/PTC3 oncogene is generated by the fusion of RET with
the RFG gene, we next wanted to address the specific contribution of
RET to the activation of the Erk8 protein. To this aim, we used a differ-
ent RET-derived oncogene, RET/MEN2B, representing a specific point
mutant of the intracellular RET domain (5), therefore lacking the RFG
component present in the RET/PTC3 chimeric protein. As shown in
Fig. 1D, increasing amounts of the RET/MEN2B protein also induced
Erk8 activation, therefore suggesting a specific role for the RET intra-
cellular tyrosine kinase domain in the activation of this MAP kinase.
Altogether, these results indicate that activated forms of the RET proto-
oncogene stimulate Erk8 activity.
A Kinase-defective Mutant for Erk8 Interferes with RET/PTC3
Signaling—The expression of the c-jun proto-oncogene is rapidly and
transiently induced by different growth factors and cellular oncogenes
(20). Among them, an oncogenic rearrangement of the RET proto-on-
cogene is able to strongly induce c-jun expression (21), therefore estab-
lishing this gene as part of the RET signaling pathway. To investigate
whether the RET/PTC3 oncogene was able to stimulate the activity of
the c-jun promoter, we took advantage of the availability of a reporter
plasmid carrying the luciferase gene under the control of the c-jun pro-
moter, pJLuc (17, 20).
A variety of thyroid cell lines have been used as model systems to
examine RET biological functions. Among them, human anaplastic thy-
roid carcinomaARO cells have the advantage to be readily transfectable
and to express endogenous Erk8 (Fig. 1A). Cotransfection of thyroid
ARO cells with the pJLuc reporter plasmid and increasing concentra-
tions of the RET/PTC3 cDNA revealed that this oncogene could
strongly induce the activity of the c-jun promoter (Fig. 2A). To evaluate
whether Erk8 activation is involved in RET/PTC3 signaling to the c-jun
promoter, we next used a dominant negative, kinase defective (data not
shown) Erk8 molecule, Erk8 KR. For these experiments, we therefore
cotransfected RET/PTC3 with the c-jun reporter plasmid and increas-
ing amounts of the Erk8 KR expression vector. As shown in Fig. 2B, the
dominant negative Erk8 molecule caused a strong, although incom-
plete, inhibition of RET/PTC3-dependent c-jun promoter stimulation,
suggesting the existence of both Erk8-dependent and Erk8-independent
pathways linking RET/PTC3 to the expression of the c-jun
proto-oncogene.
Tyrosine 981 of RET/PTC3 Is Necessary for Erk8 Activation—Tyro-
sine phosphorylated residues in the kinase domain of RET, as well as of
its derivative oncogenes, usually represent docking sites for adaptor
proteins and enzymes that are able to propagate the signal to the intra-
cellular environment (5). We therefore used RET/PTC3 molecules in
which different tyrosine phosphorylation sites have been inactivated by
mutating them to phenylalanines to ascertain the dependence of RET/
PTC3-induced Erk8 activation on the presence of these specific resi-
dues. Also, as these tyrosines have already been linked to the activation
of different specific signaling pathways (5), this approach could grant us
the possibility to suggest the participation of some of these effectors in
the modulation of Erk8 activity. In particular, tyrosine 981 binds c-Src
FIGURE 2. A, stimulation of c-jun promoter transcriptional activity in ARO cells trans-
fected with the c-jun promoter reporter plasmid (pJLuc) and increasing concentrations
of a RET/PTC3 expressing vector. B, c-jun promoter transcriptional activity in ARO cells
co-transfected with pJLuc, RET/PTC3, and a Erk8 dominant negative expressing vector
(Erk8 KR). Results represent luciferase activity in each sample, normalized for the corre-
sponding efficiency of transfection, and they are the average standard errors of trip-
licate samples from a typical experiment.
FIGURE 3. Stimulation of Erk8 activation by RET/PTC3 (PTC3) and by tyrosine-mu-
tated formsof theoncogene, in293Tcells co-transfectedwithanexpressionvector
for HA-Erk8 (-P-MAPK panel). Activation of endogenous Erk2 by RET/PTC3 and its
different mutated forms was used as a parallel control for the activity of the oncogenes
(-P-MAPK panel). The expression of HA-Erk8 (-HA panel), Erk2 (-Erk2 panel), and RET/
PTC3 wild-type and mutants (-RET panel) was also confirmed. , anti; P, phospho; con-
trol, cells transfected with -galactosidase; Kin dead, kinase dead.
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(22), tyrosine 1015 is a docking site for phospholipase C  (7), and
tyrosine 1062 is a multiple docking site that mediates most of the RET
signaling pathways (6), including Erk2 activation (23). 293T cells were
transiently transfected with the HA-Erk8 molecule, together with RET/
PTC3, RET/PTC3Y981, RET/PTC3Y1015, or RET/PTC3Y1062, respec-
tively (numbers indicating RET/PTC3 tyrosine residues correspond to
their position in the wild-type RET receptor). Surprisingly, based on the
observation that tyrosine 1062mediatesmost of the RET signaling path-
ways (6), the RET/PTC3Y1062 mutant activated Erk8 at an extent com-
parable with the RET/PTC3 molecule, whereas as expected (23), this
mutation strongly affected Erk2 activation (Fig. 3). The tyrosine 1015
mutation, involving a known binding site for phospholipase C  (7), also
did not affect Erk8 activation by RET/PTC3 (Fig. 3). Conversely, tyro-
sine 981 mutation determined a dramatic reduction in RET/PTC3-de-
pendent Erk8 activation, although such mutation proved irrelevant to
Erk2 activation (Fig. 3). As a control, RET/PTC3 Kindead, a kinase-inac-
tive form of RET/PTC3 containing a mutation in the ATP-binding cat-
alytic lysine (Lys758), was unable to activate both Erk8 and Erk2 (Fig. 3).
These results therefore imply tyrosine 981 of RET/PTC3 as a major site
recognized by signaling molecules mediating RET/PTC3-dependent
Erk8 activation. In addition, as tyrosine 981 has been previously recog-
nized as a key residue for the binding of c-Src to RET (22), they also
suggest a role for c-Src in mediating RET/PTC3-initiated signals
impinging on Erk8 activation.
Src Activity Is Dispensable for RET/PTC3-dependent Erk8 Activa-
tion—Based on the above information and on the observation that c-Src
activates Erk8 (2), we next sought to investigate whether c-Src was able
to mediate RET/PTC3-dependent Erk8 activation. A classical approach
to establish a role for Src kinases in cellular processes takes advantage of
a pyrazolo-pyrimidine compound, PP1, which binds the ATP-binding
pocket of these kinases, therefore blocking their enzymatic activity (24)
and biological functions (12). Although PP1 has been described to affect
RET kinase activity (25), a specific mutation in valine 804 in the RET
kinase domain confers resistance (50-fold increase of the IC50) to the
compound (11). We, therefore, introduced such mutation in the RET/
PTC3 kinase domain (RET/PTC3V804), rendering its activity signifi-
cantly resistant to PP1, as scored by RET/PTC3V804 autophosphoryla-
tion and activation of Erk2 (Fig. 4A). As expected, kinase activity of the
parental RET/PTC3 molecule was completely abolished at comparable
concentrations (compare the 5–10 M PP1 lanes) as evidenced by both
RET/PTC3 autophosphorylation and activation of Erk2 (Fig. 4B). Sur-
prisingly, PP1 treatment of RET/PTC3V804-transfected cells only
slightly affected Erk8 activity even at the highest doses tested (10 M)
(Fig. 4C) and after extensive times of treatment (up to 10 h of treatment,
FIGURE 4. A, the effect of PP1 on RET/PTC3V804
autophosphorylation (-P-RET panel), in 293T cells
transfected as indicated, treated for 3 hwithdiffer-
ent concentrations of the inhibitor and then ana-
lyzed by an anti-phospho RET- (-P-RET) specific
antisera. As a control, activation of endogenous
Erk2 was also scored by Western blot with anti-
phosphoMAPK antisera (-P-MAPK panel). Expres-
sion of RET/PTC3V804 and Erk2 was confirmed by
Western blot performed with anti-RET and anti-
Erk2 antisera, respectively (-RET and -Erk2 pan-
els). P, phospho. B, same as in A, using RET/PTC3 to
activate Erk8. C, Same as in A, analyzing RET/
PTC3V804-dependent Erk8 activation. D, the effect
of PP1 on RET/PTC3V804-dependent Erk8 activa-
tion (-P-MAPK panel), in 293T cells transfected as
indicated and pretreated with PP1 (5 M) for
increasing times. Erk8 expression was also con-
firmed (-HA panel). E, the effect of PP1 on RET/
PTC3V804-dependent c-Src activation, in 293T cells
transfected with RET/PTC3V804 and treated for 3 h
with increasing amounts of the drug, as indicated.
Laser densitometry was used to quantitate Src
kinase activity, and results are expressed as a per-
centage relative to Src activity in cells untreated
with PP1 (c, Me2SO). The data represent the aver-
age  standard errors of three independent
experiments. F, analysis of Erk8 activation (upper
-P-MAPK panel) in 293T cells transfectedwithHA-
Erk8, RET/PTC3, and increasing concentrations
(250 and 500 ng) of the dominant negative Src YF
KM. The expression of HA-Erk8 (-HA panel) was
also confirmed. Control, cells transfected with
-galactosidase; , anti. G, inhibition of PDGF-in-
duced c-myc promoter activity by Src YF KM. Stim-
ulation of c-myc promoter transcriptional activity
in NIH 3T3 cells transfected with the c-myc pro-
moter reporter plasmid (pMyc-Luc) and a Src dom-
inant negative expressing vectors (Src YFKM) and
then stimulated for 4 h with PDGF (12.5 ng ml1)
was performed. Results represent luciferase activ-
ity in each sample, normalized for the correspond-
ing efficiency of transfection, and they are the
average  standard errors of triplicate samples
from a typical experiment.
Erk8 Activation by RET/PTC3
APRIL 14, 2006•VOLUME 281•NUMBER 15 JOURNAL OF BIOLOGICAL CHEMISTRY 10571
at 5 M concentration) (Fig. 4D), thus excluding a role for c-Src and its
related kinases (24) in the control on RET/PTC3-induced Erk8 activa-
tion. As an additional control, the PP1 inhibitor effectively disrupted Src
activity in cells cotransfected with RET/PTC3V804 (Fig. 4E). As a com-
plementary approach to ascertain the role of Src kinases in RET/PTC3
activation of Erk8, we also used a dominant negative form of c-Src, Src
YF KM (12). As shown in Fig. 4F, overexpression of the dominant neg-
ative molecule did not affect Erk8 activation, whereas it effectively
inhibited PDGF-induced activation of the c-myc promoter (Fig. 4G)
(12). Altogether, these data clearly indicate that RET/PTC3 uses a Src-
independent pathway to activate the Erk8 MAP kinase.
c-Abl Mediates RET/PTC3-dependent Erk8 Activation—c-Abl, the
cellular homologue of the Abelson murine leukemia virus, has been
implicated in different cellular processes ranging from cell growth to
survival, cellular stress, DNA damage response, and cell migration (26).
From the structural point of view, c-Abl contains SH3, SH2, and tyro-
sine kinase domains whose arrangement and sequence very much
resemble that of c-Src (26). These observations prompted us to investi-
gate whether, similarly to Src, the activated form of c-Abl could induce
Erk8 activation and, in turn, whether c-Abl could mediate RET/PTC3
activation of Erk8. As shown in Fig. 5A, an oncogenic, activated form of
c-Abl, the Bcr/Abl fusion protein, readily induced Erk8 activation at a
level comparable with an activated form of c-Src (Src YF), used as a
positive control (2). Thus, we next decided to investigate whether c-Abl
is able to act as a link between RET/PTC3 and the stimulation of Erk8.
As an approach, we used a kinase-defective, dominant negative form of
c-Abl, Abl-KD. This dominant negative molecule strongly inhibited the
RET/PTC3-dependent activation of Erk8 (Fig. 5B), thus suggesting that
c-Abl is a likely mediator in the pathway connecting RET/PTC3 to the
activation of the Erk8 MAP kinase.
We have previously shown that tyrosine 981 in RET/PTC3 mediates
RET/PTC3-dependent Erk8 activation (Fig. 3), representing amajor site
recognized by signaling molecules intervening in such a process. We
therefore investigated whether the tyrosine 981 residue was also able to
mediate RET/PTC3 activation of c-Abl. Taking advantage of the obser-
vation that tyrosine phosphorylation of c-Abl correlates with its activa-
tion (27), we cotransfected an autophosphorylation-impaired, AU5-
tagged, c-Abl molecule, together with RET/PTC3, RET/PTC3Y981,
RET/PTC3Y1015, or RET/PTC3Y1062, respectively, immunoprecipitated
these samples by anti-AU5 antibodies, and analyzed them by anti-phos-
pho-tyrosine Western blot. As show in Fig. 5C, RET/PTC3 clearly
inducedAbl phosphorylation. Importantly, RET/PTC3Y981was strongly
impaired in its ability to induce phosphorylation of the c-Abl protein, as
compared with RET/PTC3 (Fig. 5C). In the same experiment, RET/
PTC3Y1062 and RET/PTC3Y1015 exerted more limited or no effects, as
comparedwith RET/PTC3 (Fig. 5C). Ultimately, the RET/PTC3Kindead
was unable to induce c-Abl phosphorylation, establishing a requirement
for RET/PTC3 kinase activity in c-Abl activation (Fig. 5C). Together,
these results clearly indicate that RET/PTC3, through its tyrosine 981,
can utilize an Abl-dependent pathway to stimulate Erk8 activation.
Erk8 Interacts with c-Abl and RET/PTC3—To control a vast range of
cellular processes, c-Abl interacts with a large variety of cellular pro-
teins, including phosphatases, kinases, signaling adaptors, transcription
factors, cytoskeletal proteins, and cell cycle regulators (26). To deter-
mine whether c-Abl can interact with Erk8 in vivo, 293T cells were
transfected with HA-Erk8 and either wild-type c-Abl or the control
vector, immunoprecipitated with an anti-HA antibody, and then ana-
lyzed by Western blot with an anti-Abl antisera. As shown in Fig. 6A,
FIGURE 5. A, analysis of HA-Erk8 activation in 293T cells cotransfected with Src YF, an
activated formof c-Abl, the Bcr/Abl oncogenic fusion protein. Sampleswere analyzedby
Western blot with anti-phospho MAPK (-P-MAPK) antisera. The expression of HA-Erk8
(-HA panel) and Bcr/Abl (-Abl panel) was confirmed. Control, cells transfected with
-galactosidase;, anti.B, analysis of Erk8 activation (-P-MAPKpanel) in 293T cells trans-
fected with HA-Erk8, RET/PTC3, and increasing concentrations (100, 250, and 500 ng) of
the dominant negative Abl-KD. The expression of HA-Erk8 (-HA panel) and of Abl-KD
(-AU5 panel) was also confirmed. C, stimulation of c-Abl phosphorylation by RET/PTC3
(PTC3) and by tyrosine-mutated forms of the oncogene. 293T cells were co-transfected
with an expression vector for AU5-Abl-KD together with plasmids for RET/PTC3 and its
tyrosinemutants. Samples were next immunoprecipitated (IP) by -AU5 antibodies and
then analyzed by -phospho-tyrosine antibodies (-PY). The expression of AU5-Abl-KD
(-AU5 panel) and RET/PTC3 wild-type and mutants (-RET panel) was also confirmed.
WB, Western blot.
FIGURE 6. A, In vivo interaction of Erk8 with c-Abl. 293T cells were co-transfectedwith an
expression vector for c-Abl (500 ng) together with plasmids for HA-Erk8 (500 ng) or
control vector (-galactosidase). Sampleswere next immunoprecipitated (IP) by anti-HA
antibodies and then analyzed by anti-Abl antibodies. The expression of HA-Erk8 (middle
panel) and c-Abl (lower panel) was confirmed.WB, Western blot.Control, cells transfected
with-galactosidase;, anti. B, in vivo interaction of Erk8with RET/PTC3. 293T cells were
co-transfected with an expression vector for RET/PTC3 (PTC3, 500 ng) together with
plasmids for HA-Erk8 (500 ng) or control vector (-galactosidase). Samples were next
immunoprecipitated by anti-HA antibodies and then analyzed by anti-RET antibodies.
The expression of HA-Erk8 (middle panel) and RET/PTC3 (lower panel) was confirmed.
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FIGURE 7. A, Erk8 and Erk8 expression in transiently transfected 293T cells. Control, cells transfected with -galactosidase; , anti. B, comparison of Erk8 and Erk8 nucleotide and
protein sequences in the region of the alternative splicing. C, schematic representation of Erk8 and Erk8 protein structures. The relative position of important residues and protein
domains is indicated. D, analysis of Erk8 and Erk8 activation in 293T cells cotransfected with the RET/PTC3 (PTC3) and Src YF expression vectors. Activation of endogenous Erk2 by
RET/PTC3 and Src YF was used as an additional control for the activity of the two oncogenes. The expression of HA-Erk8, HA-Erk8 (-HA panel), and Erk2 (-Erk2 panel) was also
confirmed. E, analysis of HA-Erk8 activation in 293T cells cotransfected with the RET/PTC3 (PTC3) and Src YF expression vectors and analyzed by Western blot with anti-phospho
MAPK (-P-MAPK) antisera. To be able to appreciate Erk8 low levels of phosphorylation, polyvinylidene difluoridemembranewas exposed 10min after ECL reaction. The expression
ofHA-Erk8 (-HApanel) was confirmed. F, analysis of Erk8 activation in 293T cells cotransfectedwith Bcr/Abl and Src YF expression vectors. The expressionofHA-Erk8 (-HApanel)
was confirmed.
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c-Abl clearly co-immunoprecipitated with Erk8. In an attempt to estab-
lish a role for physical interaction in the control of Erk8 activation by
RET/PTC3, we next transfected 293T cells with HA-Erk8 and either
RET/PTC3 or the control vector, immunoprecipitated with an anti-HA
antibody, and then analyzed byWestern blot with an anti-RET antisera.
Again, Erk8 evidently co-immunoprecipitated with RET/PTC3 (Fig.
6B), therefore suggesting the existence of a RET/PTC3-dependentmul-
tiprotein complex inwhich Erk8 is able to interact with both RET/PTC3
and c-Abl.
The Erk8C-terminal TailModulates Activation of theMAPKinase by
RET/PTC3—Although classical MAP kinases such as Erks, Jnks, and
p38s are only slightly larger than their minimum Ser/Thr kinase core,
the atypical Erk5, Erk7, and Erk8 MAP kinases all contain long C-ter-
minal domains whose functions are largely unknown. However, recent
FIGURE 8. A, schematic representation of Erk8 protein and of its derivative C-terminal deletion mutants. The relative position of the TEY and PXXPmotifs is also shown. B, analysis of
theactivationof Erk8andof its derivativeC-terminal deletionmutants in293T cells cotransfectedwithRET/PTC3 (PTC3) andBcr/Abl expressionvectors. TheexpressionofHA-Erk8and
of the different deletion mutants (-HA panel) was confirmed. C, analysis of HA-Erk8 activation in 293T cells cotransfected with Src YF and activated forms of c-Abl, Bcr/Abl, and Abl
Act. Samples were analyzed by Western blot with anti-phospho MAPK (-P-MAPK) antisera. The expression of HA-Erk8 (-HA panel) was confirmed. Control, cells transfected with
-galactosidase; , anti.
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experiments performed on Erk5 (28) and Erk7 (29) have demonstrated
a role for their C-terminal tail in the regulation of kinase intracellular
localization and activity. Thus, we started to investigate a role for the
Erk8 C-terminal domain in RET/PTC3-dependent activation of the
kinase.
The genomic organization of the Erk8 gene has been described pre-
viously (2). By in silico analysis of available expressed sequence tags
clones, we identified anErk8 cDNAwhose corresponding protein, when
expressed, presented a molecular mass shorter (35 kDa) than the
described Erk8 protein (60 kDa) (Fig. 7A). We named this protein
Erk8 (accession number AY994058). Comparative analysis of the
sequences for Erk8, Erk8, and the Erk8 gene (NCBI Human Genome
Resources) revealed that Erk8 corresponded to an alternatively spliced
form of Erk8 in which an alternative exon 8 (exon 8a) contained a “stop”
codon (Fig. 7B), therefore determining a 254-amino acid long protein,
lacking the Erk8 C-terminal domain (Fig. 7C). Thus, we took advantage
of the availability of this naturally occurring C-terminally truncated
protein to evaluate the role of this domain in RET/PTC3-dependent
Erk8 activation. As shown in Fig. 7D, both RET/PTC3 and Src YF were
not able to induce Erk8 activation, whereas as a control, they strongly
activated Erk8. In this regard, it is important to notice that very long
exposure (10min) of theWestern blot membrane revealed that Erk8
could still be activated by upstream stimuli (i.e. RET/PTC3 and Src YF)
(Fig. 7E). Ultimately, the experiment depicted in Fig. 7F also demon-
strated that the activated form of c-Abl, Bcr/Abl, was unable to effi-
ciently activate Erk8, therefore establishing a key role for the C-termi-
nal domain of Erk8 in the activation of this MAP kinase by various
upstream stimuli.
Erk8 C-terminal SH3-binding Motifs Are Dispensable for the Activa-
tion of the MAP Kinase—Sequence analysis of Erk8 C-terminal domain
revealed the presence of two potential SH3-binding motifs, PXXP, that
are able to bind, in vitro, the isolated SH3 domain of c-Src fused to
glutathione S-transferase (2). To ascertain the role of these two motifs,
PQLP and PRLP, in Erk8 activation, we next prepared sequential Erk8
deletion mutants progressively lacking one or both SH3-binding
sequences (Fig. 8A). Such deletion mutants were then cotransfected
with RET/PTC3 and Bcr/Abl expression vectors, to score the ability of
such activated oncogenes to induce their activation. As shown in Fig.
8B, RET/PTC3 and Bcr/Abl efficiently activated all tested deletion
mutants, including Erk8 1–373, which lacked both SH3-bindingmotifs,
therefore demonstrating that these domains do not affect Erk8 activa-
tion by different upstream stimuli. To further confirm this result, we
also exploited an activated form of c-Abl, Abl Act, lacking the SH3
domain (30), to activate Erk8. As expected, the overexpression of this
protein efficiently induced Erk8 phosphorylation (Fig. 8C), ultimately
establishing that an SH3-dependent interaction is dispensable for Erk8
activation stimulated by Abl.
DISCUSSION
The complexity of the mechanisms mediating intracellular signaling
by RET and its activated forms, the RET/PTC and MEN2 oncogenes,
has just begun to be appreciated. Indeed, the biological functions of
these proteins result from the coordinated activity of multiple kinase
cascades, whose integrated signals control renal development, histogen-
esis of the enteric nervous system and, possibly, tumor formation (5, 8,
10). Our finding that RET/PTC3 and RET/MEN2B activate Erk8 sug-
gests a role for this kinase in the transforming activity of RET-derived
oncogenes and raises the possibility of a novel Erk8-dependent signaling
pathway controlling RET biological functions.
Upon activation of different MAP kinases, a large number of tran-
scription factors appears to control the expression of several growth-
promoting genes, such as c-jun and c-fos, and, through these, control a
vast variety of cellular functions. Specifically, the c-jun promoter has
already been shown to represent a key site for the integration of signals
coming fromboth cellular oncogenes (17) and extracellular ligands (20).
Therefore, our observation that a dominant negative Erk8 molecule
only partially inhibits the activation of the c-jun promoter is not sur-
prising. Indeed, we have previously demonstrated that signaling from
RET impinges on the activation of at least anotherMAP kinase, Jnk (23),
which is able to control the activity of the c-jun promoter (20). We can
therefore expect Erk8 to be part of the complex network of kinases,
whose activation ultimately determines the specific biological response
to the activation of RET and its related oncogenes in different cellular
environments.
Interestingly, we have shown that Erk8 activation depends on the
integrity of tyrosine 981, whereas tyrosine 1062mutation does not affect
RET/PTC3-dependent activation of the kinase. This result clearly dif-
ferentiates Erk8 from other MAP kinases already involved in RET sig-
naling whose activation, on the contrary, strictly depends on RET tyro-
sine 1062 (31). Although RET tyrosine 981 has been previously
recognized as a docking site for c-Src (22) and this kinase modulates
Erk8 activation (2), surprisingly, RET/PTC3 activation of Erk8 does not
depend on c-Src. This result therefore suggests that additional mole-
cules interact with tyrosine 981 of RET/PTC3 and are responsible for
the control of Erk8 activity. Indeed, in this report, we present evidences
that c-Abl controls RET/PTC3-dependent Erk8 activating phosphoryl-
ation. As a corollary to this finding, we show for the first time that c-Abl
is able to mediate RET-dependent signaling pathways. Not only does
RET/PTC3 induce c-Abl phosphorylation, but such a phenomenon also
seems to be mediated by tyrosine 981, in line with our observation that
this tyrosine mediates Erk8 activation. These findings strongly support
each other, especially considering that, up to now, the only known sig-
nalingmolecule downstream of this tyrosine was c-Src, whereasmost of
the other RET effectors depended on the integrity of tyrosine 1062.
c-Abl as well as c-Src contain well characterized SH3 domains, with a
high degree of conservation in terms of sequence identity and structure
(26). In c-Abl, this domain is important both for interaction with differ-
ent proteins and for participation to an intramolecular regulatorymech-
anism (32). On the other hand, Erk8 contains two putative SH3-binding
sites in its c-terminal tail (2). As the c-Src SH3 domain interacts in vitro
with Erk8 (2), we tested the possibility that the c-Abl SH3 domain could
modulate Erk8 activity. We show that deletion of the putative Erk8
SH3-binding sites does not affect the activation of the MAP kinase by
both Bcr/Abl and RET/PTC3. Moreover, an activated form of c-Abl
lacking the SH3 domain, Abl Act (30), efficiently induces Erk8 phospho-
rylation, again suggesting that an SH3-dependent interaction is dispen-
sable for Erk8 phosphorylation. Nonetheless, it is possible that a com-
plex between c-Abl and Erk8 may be necessary for the correct
localization of the MAP kinase to particular cellular subcompartments
to have full access to pools of specific substrates. Further work will be
required to address these issues and to understand the role of Erk8 in
RET physiological and pathological functions.
Acknowledgments—We are grateful to C. B. Bruni for support during this
work; M. Abe and H. Varmus for reagents; J. S. Gutkind and M. J. Marinissen
for discussion and critical reading of the manuscript; and V. Guarino for help
under “Materials and Methods.”
REFERENCES
1. Widmann, C., Gibson, S., Jarpe, M. B., and Johnson, G. L. (1999) Physiol. Rev. 79,
143–180
Erk8 Activation by RET/PTC3
APRIL 14, 2006•VOLUME 281•NUMBER 15 JOURNAL OF BIOLOGICAL CHEMISTRY 10575
2. Abe, M. K., Saelzler, M. P., Espinosa, R., III, Kahle, K. T., Hershenson, M. B., Le Beau,
M. M., and Rosner, M. R. (2002) J. Biol. Chem. 277, 16733–16743
3. Schuchardt, A., D’Agati, V., Larsson-Blomberg, L., Costantini, F., and Pachnis, V.
(1994) Nature 367, 380–383
4. Airaksinen, M. S., and Saarma, M. (2002) Nat. Rev. Neurosci. 3, 383–394
5. Santoro, M., Melillo, R. M., Carlomagno, F., Vecchio, G., and Fusco, A. (2004) Endo-
crinology 145, 5448–5451
6. Kurokawa, K., Kawai, K., Hashimoto, M., Ito, Y., and Takahashi, M. (2003) J. Intern.
Med. 253, 627–633
7. Borrello,M. G., Alberti, L., Arighi, E., Bongarzone, I., Battistini, C., Bardelli, A., Pasini,
B., Piutti, C., Rizzetti, M. G., Mondellini, P., Radice, M. T., and Pierotti, M. A. (1996)
Mol. Cell. Biol. 16, 2151–2163
8. Pasini, B., Ceccherini, I., and Romeo, G. (1996) Trends Genet 12, 138–144
9. Sherman, S. I. (2003) Lancet 361, 501–511
10. Nikiforov, Y. E. (2002) Endocr. Pathol. 13, 3–16
11. Carlomagno, F., Guida, T., Anaganti, S., Vecchio,G., Fusco, A., Ryan, A. J., Billaud,M.,
and Santoro, M. (2004) Oncogene 23, 6056–6063
12. Chiariello, M., Marinissen, M. J., and Gutkind, J. S. (2001) Nat. Cell Biol. 3, 580–586
13. Carlomagno, F., De Vita, G., Berlingieri, M. T., de Franciscis, V., Melillo, R. M.,
Colantuoni, V., Kraus, M. H., Di Fiore, P. P., Fusco, A., and Santoro, M. (1996) EMBO
J. 15, 2717–2725
14. Melillo, R. M., Santoro, M., Ong, S. H., Billaud, M., Fusco, A., Hadari, Y. R., Schless-
inger, J., and Lax, I. (2001)Mol. Cell. Biol. 21, 4177–4187
15. Lobo, V., Luquero, C. I. A., Alvarez-Vallina, L., Tipping, A. J., Viniegra, J. G., Losa,
J. H., Cobo, C. P., Moya, E. M. G., Cruz, J. G., Melo, J. V., Cajal, S. R. Y., and Sanchez-
Prieto, R. (2005) Biochem. J. 387, 231–238
16. Sanchez-Prieto, R., Sanchez-Arevalo, V. J., Servitja, J. M., and Gutkind, J. S. (2002)
Oncogene 21, 974–979
17. Chiariello, M., Marinissen, M. J., and Gutkind, J. S. (2000) Mol. Cell. Biol. 20,
1747–1758
18. Zhang, W., Morris, Q. D., Chang, R., Shai, O., Bakowski, M. A., Mitsakakis, N., Mo-
hammad, N., Robinson, M. D., Zirngibl, R., Somogyi, E., Laurin, N., Eftekharpour, E.,
Sat, E., Grigull, J., Pan, Q., Peng,W. T., Krogan, N., Greenblatt, J., Fehlings,M., van der
Kooy, D., Aubin, J., Bruneau, B. G., Rossant, J., Blencowe, B. J., Frey, B. J., and Hughes,
T. R. (2004) J. Biol. (Bronx N. Y.) 3, 21
19. Santoro, M., Dathan, N. A., Berlingieri, M. T., Bongarzone, I., Paulin, C., Grieco, M.,
Pierotti, M. A., Vecchio, G., and Fusco, A. (1994) Oncogene 9, 509–516
20. Marinissen,M. J., Chiariello,M., Pallante,M., andGutkind, J. S. (1999)Mol. Cell. Biol.
19, 4289–4301
21. Ishizaka, Y., Takahashi, M., Ushijima, T., Sugimura, T., and Nagao, M. (1991) Bio-
chem. Biophys. Res. Commun. 179, 1331–1336
22. Encinas, M., Crowder, R. J., Milbrandt, J., and Johnson, E. M., Jr. (2004) J. Biol. Chem.
279, 18262–18269
23. Chiariello,M., Visconti, R., Carlomagno, F.,Melillo, R.M., Bucci, C., de Franciscis, V.,
Fox, G. M., Jing, S., Coso, O. A., Gutkind, J. S., Fusco, A., and Santoro, M. (1998)
Oncogene 16, 2435–2445
24. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer,
E. J., Pollok, B. A., and Connelly, P. A. (1996) J. Biol. Chem. 271, 695–701
25. Carlomagno, F., Vitagliano, D., Guida, T., Napolitano, M., Vecchio, G., Fusco, A.,
Gazit, A., Levitzki, A., and Santoro, M. (2002) Cancer Res. 62, 1077–1082
26. Hantschel, O., and Superti-Furga, G. (2004) Nat. Rev. Mol. Cell Biol. 5, 33–44
27. Plattner, R., Kadlec, L., DeMali, K. A., Kazlauskas, A., and Pendergast, A. M. (1999)
Genes Dev. 13, 2400–2411
28. Buschbeck, M., and Ullrich, A. (2005) J. Biol. Chem. 280, 2659–2667
29. Abe,M. K., Kahle, K. T., Saelzler,M. P., Orth, K., Dixon, J. E., and Rosner,M. R. (2001)
J. Biol. Chem. 276, 21272–21279
30. Mayer, B. J., and Baltimore, D. (1994)Mol. Cell. Biol. 14, 2883–2894
31. Hayashi, H., Ichihara, M., Iwashita, T., Murakami, H., Shimono, Y., Kawai, K., Kuro-
kawa, K.,Murakumo, Y., Imai, T., Funahashi, H., Nakao, A., and Takahashi,M. (2000)
Oncogene 19, 4469–4475
32. Wang, J. Y. J. (2004) Nat. Cell Biol. 6, 3–7
Erk8 Activation by RET/PTC3
10576 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 281•NUMBER 15•APRIL 14, 2006
